Use the hyperlinks, where available to access additional clinical trial information.
An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer
Other Non-Commercial Sponsor
Cancer Council of NSW & St Vincent's Hospital, Sydney
Eligible patients will be randomised to one of three groups. Group 1 patients will receive letrozole and promethium; patients in Group 2 will receive tamoxifen and promethium; and Group 3 will receive letrozole alone. All assigned treatments will be administered daily for two weeks prior to surgery.